ÂÜÀòÂÒÂ×

Anthony Alfred Chiurco, MD Professor of Neurological Surgery, Vice Chair of Clinical Services in the Department of Neurological Surgery, and Chief of the Division of Neuro-Oncology at Thomas Jefferson University Hospital.

As Chief Medical Officer at Imvax, Inc., Dr. Andrews communicates and engages with clinicians, researchers, and other key opinion leaders in the field regarding clinical development activities and potential product development. He develops strategic plans for the company’s product portfolio to ensure that development programs meet quality and safety standards required by patients, health care providers, and regulatory agencies. Dr. Andrews has a 30-year experience as an academic brain tumor neurosurgeon, completing residency at New York Presbyterian Cornell and a Fellowship at Memorial Sloan Kettering Cancer Center, both in New York, NY. As a junior attending neurosurgeon, he received a prestigious NIH Physician Scientist Award to study brain tumors and has devoted his career to find better treatment for glioblastoma. He currently resides at Thomas Jefferson University Hospital where he is Professor and Vice Chair of Clinical Services, Department of Neurological Surgery, and Chief of the Division of Neuro-Oncology.

Dr. Andrew’s raised nearly $7M dollars in philanthropy over a 20-year period to advance this promising immunotherapy platform for GBM, collaborating closely with his colleague Dr. Craig Hooper, a talented neuro-immunologist. He established the Brain Tumor Division at Thomas Jefferson University Hospital in 1995 and served as its Chief, expanding the Division to four neurosurgeons and two neuro-oncologists before stepping down to assume his role as a founder of Imvax, Inc. in 2015. Under his leadership, the Division became a national leader performing over 1,100 brain tumor treatments a year. His vision with Imvax, Inc. is to accelerate the development of this promising vaccine treatment.